Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

STAAR Surgical Receives FDA Clearance For The Epiphany(TM) Injector System
STAAR Surgical Company (Nasdaq: STAA), a leading developer, manufacturer and marketer of minimally invasive ophthalmic products, today announced that the FDA has granted 510(k) clearance for its Epiphany Injector System for use with the Affinity(TM) Collamer(R) Three-Piece NTIOL and the Elastimide(TM) Silicone NTIOL. Introduction of the Epiphany will usher in a new era of insertion devices for the company and pave the way for the future introduction of a preloaded injector for the U.S. market.
generic viagra online
Social Care Workforce Not Ready To Deliver Dementia Care - MPs
A report published revealed the social care workforce is unfit to deliver quality care for people with dementia.
News of the day
Michigan Lawmakers Approve Request For State Health Agency To Use Private Funds For HIV/AIDS Program
The Michigan Department of Community Health recently received approval from state lawmakers to use $3.2 million in private funds to support the state"s AIDS Drug Assistance Program, the AP/Detroit News reports. Michigan"s House and Senate Appropriations Committees also approved requests by other state agencies to shift funds as a means to continue public programs that were affected by budget cuts ordered last month (Eggert, AP/Detroit News, 6/4).
Medical Devices

Advanced Prostate Cancer - New Review On PROSTVAC(TM) Published By Key Investigators From NCI

A just published Review in the publication "Expert Opinion on Investigational Drugs", Volume 18, Issue 7 2009, confirms the previous published information on PROSTVAC(TM). This is the most comprehensive and updated Review on PROSTVAC(TM) so far. Quote from the article: "Preliminary clinical trials have indicated negligible toxicity, and Phase II trials have suggested a survival benefit after treatment with PROSTVAC(TM), especially in patients with indolent disease characteristics." Anders Hedegaard, President & CEO of Bavarian Nordic said: "We are very pleased that the scientific experts once again confirm their positive view on PROSTVAC(TM) and the potential use of the vaccine in earlier stages of the disease. We are looking forward to publish more data at a later stage." Background information: PROSTVAC(TM) is a therapeutic vaccine moving into late stage clinical development that has the potential to extend the lives of people with advanced prostate cancer. Administered subcutaneously, it induces a specific, targeted immune response that attacks prostate cancer cells. Conventional chemotherapy currently used to treat prostate cancer has limited survival rates and is often associated with numerous side effects. In contrast, PROSTVAC(TM) has the potential to extend survival with improved quality of life. PROSTVAC is being developed in collaboration with the National Cancer Institute under a Cooperative Research and Development Agreement with Bavarian Nordic"s U.S.-based subsidiary, BN ImmunoTherapeutics. In clinical trials to date PROSTVAC(TM) and related PSA containing poxviral vaccines have been investigated in more than 500 patients for 10 years. Bavarian Nordic


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009